Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NX78

UPID:
TM260_HUMAN

ALTERNATIVE NAMES:
Transmembrane protein 260

ALTERNATIVE UPACC:
Q9NX78; A8KAN4; B3KPF5; Q0VAA1; Q86XE1

BACKGROUND:
The enzyme Protein O-mannosyl-transferase TMEM260, alternatively known as Transmembrane protein 260, is pivotal in protein modification through O-mannosylation. This process targets the hydroxyl groups of serine or threonine residues, notably affecting proteins like MET and MST1R/RON by adding single mannose glycans.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Protein O-mannosyl-transferase TMEM260 could open doors to potential therapeutic strategies, especially considering its link to Structural heart defects and renal anomalies syndrome. This insight offers a promising avenue for addressing the complex clinical features associated with this genetic condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.